Molecular Farming

The commonly used term ‘molecular farming’ describes the large‐scale production of valuable proteins in transgenic plants, including antibodies, vaccines, other pharmaceuticals and industrial proteins. Compared to traditionally used systems such as microbial cultures, plants offer many advantages with respect to economy, quality and safety. The organism or material into which the new genetic information is inserted is often referred to as the expression system since it serves as the system for “expressing” the new product. Plant molecular farming is currently being pursued to address either the increased demand for proteins that cannot be produced in sufficient quantities in either microbial or animal cell cultures, or as a means to produce proteins that cannot be expressed in microbial or animal cell cultures. Vaccines are another area of research in molecular farming. Early-stage clinical trials have been completed on customized, patient-specific vaccines for Non-Hodgkins Lymphoma. These plant-produced vaccines can be generated in 6 to 10 weeks, a much shorter time frame than conventional methods These plant-produced vaccines can be generated in 6 to 10 weeks, a much shorter time frame than conventional methods. As mentioned previously, edible vaccines, although enthusiastically discussed in recent years, have virtually been abandoned.

The benefits of molecular farming have been demonstrated over the last 15 years through the sustained efforts of a growing number of European research groups, many of which have participated in the COST action “Molecular farming: plants as a production platform for high value protein

Plant molecular farming (PMF) is a new branch of plant biotechnology, where plants are engineered to produce recombinant pharmaceutical and industrial proteins in large quantities. As an emerging subdivision of the biopharmaceutical industry, PMF is still trying to gain comparable social acceptance as the already established production systems that produce these high valued proteins in microbial, yeast, or mammalian expression systems. The products of pharming are recombinant proteins or their metabolic products. Recombinant proteins are most commonly produced using bacteria or yeast in a bioreactor, but pharming offers the advantage to the producer that it does not require expensive infrastructure, and production capacity can be quickly scaled to meet demand, at greatly reduced cost.

  • Scope of molecular farming
  • Production of Industrial enzymes and biodegradable plastics
  • Production of antibodies
  • Metabolic engineering for production of fatty acids, Industrial oils, Terpenoids and flavonoids
  • Growth and production kinetics of cell culture in shake flasks

Related Conference of Molecular Farming

March 20-22, 2017

8th World Congress and Expo on Cell & Stem Cell Research

Orlando, Florida, USA
June 19-20, 2017

2nd International Conference on Bioscience

London, UK
July 03-05, 2017

7th World Summit on Plant Genomics

Bangkok, Thailand
July 20-22, 2017

14th Asia-Pacific Biotechnology Congress

Melbourne, Australia
August 10-12, 2017

3rd Annual Congress and Expo on Bioscience

Beijing, China
August 14-15, 2017

3rd World Congress on Human Genetics

Edinburgh, Scotland
Sep 18-19, 2017

World Summit on Cell Signalling and Cancer Therapy

Toronto, Canada
December 04-06, 2017

2nd World Biotechnology Congress

Sao Paulo, Brazil
September 21-22, 2017

International Conference on Clinical and Medical Genetics

Toronto, Canada
September 25-27, 2017

17th Euro Biotechnology Congress

Berlin, Germany
September 27-28, 2017

Annual Summit on Cell Therapy

Chicago, USA
Oct 19-20, 2017

Bio America 2017

New York, USA
November 02-03, 2017

2nd World Congress on Human Genetics & Genetic Disorders

Toronto, Canada
December 11-12, 2017

3rd World Bio Summit & Expo

Dubai, UAE

Molecular Farming Conference Speakers

Recommended Sessions

Related Journals

Are you interested in